Protagonist Therapeutics Chief R&D Strategy Officer David Liu transitions to part-time advisor due to health reasons

Protagonist Therapeutics, Inc

David Liu stepped down as Chief R&D Strategy Officer effective Jan 1, 2023, due to health reasons.
He will continue as a part-time R&D Strategy Advisor, no longer an executive officer.
No replacement named for the role of Chief R&D Strategy Officer.
Liu is no longer a Section 16 officer, reducing executive team.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

David Liu

Chief R&D Strategy Officer

PTGX · Protagonist Therapeutics, Inc

Effective: 2023-01-01
Filed: January 6, 2023, 6:59 PM ET

Effective January 1, 2023, David Liu, Protagonist Therapeutics, Inc.’s Chief R&D Strategy Officer, transitioned to a part-time R&D Strategy Advisor due to health reasons.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

David Liu changed role as Chief R&D Strategy Officer at Protagonist Therapeutics, Inc.

Action: transitioned to a part-time R&D Strategy Advisor
Role: Chief R&D Strategy Officer

Exact text from the filing

Effective January 1, 2023, David Liu, Protagonist Therapeutics, Inc.’s Chief R&D Strategy Officer, transitioned to a part-time R&D Strategy Advisor due to health reasons.

View on SEC.gov

Protagonist Therapeutics, Inc filing history →

Source: SEC EDGAR

accession 0001104659-23-001872

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.